.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
This randomized clinical trial investigated whether once-weekly semaglutide could reduce alcohol consumption and craving in adults with alcohol use disorder. Participants received low-dose semaglutide or placebo over nine weeks. Compared with placebo, semaglutide reduced the amount of alcohol consumed during a laboratory self-administration task and significantly reduced weekly alcohol craving. Some, but not all, measures of weekly alcohol consumption also improved, and participants who smoked cigarettes at baseline showed greater relative reductions in cigarettes per day. These findings provide preliminary clinical evidence that GLP-1 receptor agonists may influence reward-related behaviours beyond their established metabolic effects. However, the study was relatively small and short, so it cannot establish long-term effectiveness, relapse prevention or suitability as a routine treatment for alcohol use disorder. Larger trials are needed to clarify clinical significance, dosing and safety.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This randomized clinical trial investigated whether once-weekly semaglutide could reduce alcohol consumption and craving in adults with alcohol use disorder. Participants received low-dose semaglutide or placebo over nine weeks. Compared with placebo, semaglutide reduced the amount of alcohol consumed during a laboratory self-administration task and significantly reduced weekly alcohol craving. Some, but not all, measures of weekly alcohol consumption also improved, and participants who smoked cigarettes at baseline showed greater relative reductions in cigarettes per day. These findings provide preliminary clinical evidence that GLP-1 receptor agonists may influence reward-related behaviours beyond their established metabolic effects. However, the study was relatively small and short, so it cannot establish long-term effectiveness, relapse prevention or suitability as a routine treatment for alcohol use disorder. Larger trials are needed to clarify clinical significance, dosing and safety.
Today
Overexpression of glycoprotein nonmetastatic melanoma protein B (GPNMB) mediates resistance to CDK4/6 inhibitors like abemaciclib and palbociclib in ER+ breast cancer through integrin-driven AKT/ERK signaling. Targeting GPNMB with antibody-drug conjugates like glembatumumab vedotin may overcome this resistance.
Today
A secondary analysis of the MOMS clinical trial reveals that infant sex does not influence neonatal opioid withdrawal syndrome severity in buprenorphine-exposed newborns. Maternal co-exposures and clinical factors drive outcomes, highlighting the need for objective assessment and supportive breastfeeding.
Today
A comparative study reveals magnetic resonance elastography outperforms ultrasound elastography in assessing liver fibrosis in Fontan-associated liver disease, demonstrating stronger histological agreement and superior discrimination.
Today
A systematic review and meta-analysis highlights the substantial impact of plyometric jump training on jump performance, reactive strength, and landing kinematics in female team-sport athletes, providing evidence-based programming guidelines for sports medicine and orthopedics.
Today
A comprehensive review of the role of growth hormone in diabetic kidney disease and podocytopathy. Learn how elevated GH activates ZEB2, Notch, and TGF-beta1, driving podocyte loss and glomerulosclerosis, and explore novel targeted therapeutic approaches.
Today
